Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by BlaineBorgon Jul 06, 2021 9:48am

123 Views

Post# 33498356

Worst Case Scenario Now Is Running The Company Into The...

Ground So Kulwant Malhi can come in and do a sub penny takeover. They will do whatever it takes to keep their gravy train moving for insiders. Chris Moreau is a huge disappointment. Ne's unqualified for the job and the directors of the company are no better. Algernon has got to be one of the worst performing stocks YOY listed on the CSE. Meanwhile, you passive Canadians just suck it up.

BB

<< Previous

Bullboard Posts

Next >>

Revolutionizing medical imaging with nanocarbon-based contrast drugs